Drug Profile

Tenofovir alafenamide - Gilead Sciences

Alternative Names: GS-7340; GS-7340-02; GS-7340-03; TAF; Tenofovir alafenamide fumarate; Vemlidy

Latest Information Update: 01 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Gilead Sciences
Developer Gilead Sciences; University Hospital Inselspital; University of California
Class Amines; Antivirals; Phosphorus compounds; Propionates; Purines; Small molecules
Mechanism of Action Nucleotide reverse transcriptase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - HIV infections
New Molecular Entity No

Highest Development Phases

Marketed Hepatitis B
Phase III HIV-1 infections
Phase II HIV infections

Most Recent Events

01 Apr 2024 Launched for Hepatitis B (In children) in USA (PO)
28 Mar 2024 Registered for Hepatitis B (In children) in USA (PO)
10 Nov 2023 Updated efficacy and adverse events data from a phase II trial in Hepatitis B presented at the 74^th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com